drugset / Trial / NCT05647122
First in Human Study of AZD9592 in Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.
Timeline
- Start
- 2022-12-21
- Primary completion
- 2028-08-03
- Completion
- 2028-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD9592 | Unknown | — | — |
| Background | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Background | Leucovorin | Small molecule | — | Intravenous |
| Background | Osimertinib | Small molecule | — | Oral |
| Background | fluorouracil | Small molecule | — | Intravenous |